IELSG37A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Participants required:540 (enrolment completed)
Investigator responsible(s):M. Martelli, A.J. Davies, M. Gospodarowicz, E. Zucca
Objective(s):To evaluate the possibility to spare the radiotherapy in PMBCL patients, who have become “PET-negative” after a combined R-chemotherapy.

Home | Go to Studies